Fabrice Lucien, PhD

Our paper on moPepGen is finally out in Nature Biotechnology! moPepGen is a fast graph-based tool for systematically predicting and detecting non-canonical peptides, revealing the “dark side” of the proteome. Hoping it opens new doors in proteogenomics. nature.com/articles/s4158…

Congrats on @MayoUrology published study led by Drs @VRodriguezBravo and @DomingoDomenech discover that nucleoplasm-residing nucleoporins drive #ProstateCancer progression & immune evasion by switching on oncogenic signaling from deep within the nucleus! vist.ly/3z88z

Our new humanized both PD-1 and PD-L1 mice are now available at the Jax lab with an RRID. Thank you all for your interest in use of this mouse model to shorten preclinical and clinical space for targeting this pathway. The link for strain details: jax.org/strain/040677

😱 Updates on #NCI R01 payline: 4th percentile for EI/NI, 10th %ile for ESI. Awarded R01: 17% budget cuts R21 payline: 7%ile cancer.gov/grants-trainin…

What does it take to translate urinary EV biomarkers to the clinic? Glad to have contributed to this excellent review led by Marvin Droste and Uta Erdbrügger in @ISEV_Journals @IsevOrg isevjournals.onlinelibrary.wiley.com/doi/10.1002/je…

#PERSIAN trial explores SBRT benefits in oligometastatic hormone-sensitive #ProstateCancer. @GiulioFrancoli1 @AOUCareggi sits down with @neerajaiims @huntsmancancer to discuss SBRT added to ADT plus apalutamide in oligometastatic #HSPC. Preliminary analysis of 87 patients shows a…

jamanetwork.com/journals/jaman… TMT for MIBC is a crucial treatment option for our patients. 💵However, its current costs are unsustainable, especially with the growing interest in expanding its use.

🚫 No dyes. No bleaching. 🔬 Just AI + label-free microscopy = vivid virtually stained images New in @NatMachIntell: A deep learning model that enables robust virtual staining across microscopes, cell types & conditions. #CZBiohubSF @mattersOfLight explains:

Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. @ChadTangMD @MDAndersonNews sits down with @l_ballas @CedarsSinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic…

2️⃣ Metastasis Directed Therapy in Oligometastatic Prostate Cancer 👥 With @drmaneesh_singh & @piet_ost 🧠 A deep dive into MDT’s role: trial data, timing, integration with systemic Rx. 🚀 Covering both HSPC and CRPC. Read 📖 doi.org/10.1016/j.semr… With an image for the ages!

Thanks @urotoday for highlighting our recent work on tumor-derived EVs for risk stratification and prediction of response to SBRT in omCSPC @MayoUrology @MayoRadOnc

Congrats to @MayoUrology researchers on their ⭐first-ever exploration of a new frontier in advanced urothelial carcinoma! Historically consolidative surgery was rare in metastatic UC but with unprecedented responses to EV/Pembro the paradigm is shifting. vist.ly/3n5mvyg

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative…

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119) ⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb! ➡️link shorturl.at/unfn5

At Mayo, we have long recognized AI as a tool to enhance human expertise. @NYTimes takes a closer look at how our different view has allowed our radiologists to improve accuracy, accelerate diagnosis, and advance cures: nyti.ms/4knWFYj

EV enthusiasts, we have a call for submission to the journal Clinical Proteomics. Method optimization, standardization and biomarker research on extracellular vesicles biomedcentral.com/collections/EV…

“According to the White House document, the proposal would cut all non-defence spending by 23% but targets the US National Science Foundation for a 56% funding reduction, and would slash the budget of the US National Institutes of Health by roughly 40%.” nature.com/articles/d4158…

EVs flip-flops and sunglasses. #ISEV2026

So proud of Chisom Uzendu, PhD candidate, for winning a Poster Award. Very well deserved. @MayoUrology

#ISEV2025 scholarship winners! 👏